Human ヒトSP-c プロモーター, Human SDC4 gene cDNA, Human ROS1 gene cDNA, SV40 Splicing + Poly(A) Necessary documents for ordering:<ol><li>Order form (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_4.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_b.docx">English</A>)</li><li>Category I MTA: MTA for distribution with RIKEN BRC (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_5.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_c.docx">English</A>)</li><li>Acceptance of responsibility for living modified organism (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_7.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_g.docx">English</A>)</li></ol> Cancer Research C57BL/6J-Tg(SFTPC-SDC4/ROS1)141Tno C57BL/6J-Tg(SFTPC-SDC4/ROS1)141Tno D (more than 6 months) Mice model for the lung adenocarcinoma. Transgenice mice expressing SDC4/ROS1 fusion protein under the control of the human SPC promoter. 肺がん発症モデルマウス。ヒト肺腺がんで発見された融合タンパク(SDC4/ROS1)を発現するトランスジェニックマウス。ヒトSPC (SFTPC) 遺伝子プロモーターにより、融合タンパクの発現は肺胞上皮に特異的。 D(6か月以上) true Developed by Tetsuo Noda, The Cancer Institute of JFCR. C57BL/6J background. #141 #141 RBRC09697 In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of the following literature(s) designated by the DEPOSITOR is requested. Carcinogenesis, 37, 452-460 (2016).For use of the BIOLOGICAL RESOURCE by a for-profit institution, the RECIPIENT must reach agreement on terms and conditions of use of it with DEPOSITOR and must obtain a prior written consent from the DEPOSITOR. The RECIPIENT must contact the DEPOSITOR in the case of application for any patents or commercial use based on the results from the use of the BIOLOGICAL RESOURCE. 公益財団法人がん研究会がん研究所・野田哲生らにより開発。C57BL/6J背景。 条件を付加する。<br>研究成果の公表にあたって寄託者の指定する文献を引用する。Carcinogenesis, 37, 452-460 (2016).<br>営利機関の利用希望者は、事前に利用条件等につき寄託者と合意し、提供承諾を得ること。利用者が本件リソースを使用して得られた研究成果に基づき特許等の申請、及び事業活動を行う場合は、寄託者と別途協議を行う。